CR20230527A - Composición farmacéutica de pembrolizumab y su uso - Google Patents
Composición farmacéutica de pembrolizumab y su usoInfo
- Publication number
- CR20230527A CR20230527A CR20230527A CR20230527A CR20230527A CR 20230527 A CR20230527 A CR 20230527A CR 20230527 A CR20230527 A CR 20230527A CR 20230527 A CR20230527 A CR 20230527A CR 20230527 A CR20230527 A CR 20230527A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- pembrolizumab
- pharmaceutical composition
- infectious diseases
- malignant neoplasms
- Prior art date
Links
- 229960002621 pembrolizumab Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere al campo de la farmacia y la medicina, específicamente a las composiciones farmacéuticas del anticuerpo anti-PD-1 pembrolizumab, que pueden ser composiciones acuosas o liofilizadas. La invención se refiere además al uso de dichas composiciones para el tratamiento de neoplasias malignas o enfermedades infecciosas, así como al uso de dichas composiciones para producir un medicamento destinado a tratar neoplasias malignas o enfermedades infecciosas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2021112111A RU2791857C2 (ru) | 2021-04-27 | Фармацевтическая композиция пембролизумаба и ее применение | |
PCT/RU2022/050140 WO2022231481A1 (en) | 2021-04-27 | 2022-04-27 | Pharmaceutical composition of pembrolizumab and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230527A true CR20230527A (es) | 2024-02-13 |
Family
ID=83848424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230527A CR20230527A (es) | 2021-04-27 | 2022-04-27 | Composición farmacéutica de pembrolizumab y su uso |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4329729A1 (es) |
CN (1) | CN117835965A (es) |
AR (1) | AR125470A1 (es) |
CL (1) | CL2023003209A1 (es) |
CO (1) | CO2023014166A2 (es) |
CR (1) | CR20230527A (es) |
EC (1) | ECSP23081880A (es) |
MA (1) | MA62939A1 (es) |
MX (1) | MX2023012745A (es) |
TW (1) | TW202308692A (es) |
WO (1) | WO2022231481A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024171082A1 (en) * | 2023-02-16 | 2024-08-22 | Sun Pharmaceutical Industries Limited | Stable protein compositions of anti-pd1 antibody |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3283107T (pt) * | 2015-04-17 | 2020-08-31 | Bristol Myers Squibb Co | Composições compreendendo uma combinação de ipilimumab e nivolumab |
US11608357B2 (en) * | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
WO2020097141A1 (en) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
-
2022
- 2022-04-26 TW TW111115864A patent/TW202308692A/zh unknown
- 2022-04-27 EP EP22796265.1A patent/EP4329729A1/en active Pending
- 2022-04-27 MA MA62939A patent/MA62939A1/fr unknown
- 2022-04-27 CR CR20230527A patent/CR20230527A/es unknown
- 2022-04-27 WO PCT/RU2022/050140 patent/WO2022231481A1/en active Application Filing
- 2022-04-27 CN CN202280030892.2A patent/CN117835965A/zh active Pending
- 2022-04-27 MX MX2023012745A patent/MX2023012745A/es unknown
- 2022-04-27 AR ARP220101106A patent/AR125470A1/es unknown
-
2023
- 2023-10-23 CO CONC2023/0014166A patent/CO2023014166A2/es unknown
- 2023-10-25 EC ECSENADI202381880A patent/ECSP23081880A/es unknown
- 2023-10-26 CL CL2023003209A patent/CL2023003209A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022231481A1 (en) | 2022-11-03 |
CN117835965A (zh) | 2024-04-05 |
AR125470A1 (es) | 2023-07-19 |
TW202308692A (zh) | 2023-03-01 |
ECSP23081880A (es) | 2023-11-30 |
CL2023003209A1 (es) | 2024-05-31 |
MX2023012745A (es) | 2023-11-09 |
EP4329729A1 (en) | 2024-03-06 |
MA62939A1 (fr) | 2024-02-29 |
CO2023014166A2 (es) | 2024-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500396A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof | |
WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
MX2023006541A (es) | Formulaciones de dosis fija. | |
EA033456B1 (ru) | Конъюгаты антитело-лекарственное средство, содержащие пептидомиметические линкеры | |
CU24117B1 (es) | Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica | |
MX2011013150A (es) | Composicion farmaceutica para uso en oftalmologia medica y veterinaria. | |
BR112015005117A2 (pt) | métodos de tratamento da doença de alzheimer e suas composições farmacêuticas | |
WO2017128917A8 (zh) | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 | |
TN2014000131A1 (en) | Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments | |
MX2024000208A (es) | Restos de administracion terapeutica novedosos y usos de estos. | |
ZA202302155B (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
SG11201910113PA (en) | Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate | |
MX2023012745A (es) | Composicion farmaceutica de pembrolizumab y su uso. | |
MX2011008261A (es) | FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1. | |
UA120083C2 (uk) | АНТИМЕТАСТАТИЧНІ 2H-СЕЛЕНОФЕНО[3,2-h]ХРОМЕНИ, ЇХ СИНТЕЗ ТА СПОСОБИ ЗАСТОСУВАННЯ ЦИХ АГЕНТІВ | |
MX2021007032A (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos. | |
MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
MX2022015232A (es) | Composicion farmaceutica acuosa de levilimab y su uso. | |
BR112017015474A2 (pt) | inibidores de bace1 | |
JOP20220045A1 (ar) | تركيبة صيدلانية مائية من جسم مضاد ANTI-PD1 برولجوليماب prolgolimab واستخدامها | |
MX2019008603A (es) | Una composicion farmaceutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevencion de la enfermedad de alzheimer. |